FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL             |           |  |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

|  |   |  |   |          | UI                           | Secur  | JII 30(  | טו נו (וו)                              | ie ilives     | sunent (  | Company Act             | 01 1340   |                                |   |   |  |                                      |  |  |  |
|--|---|--|---|----------|------------------------------|--|--|---|---------------|---|-------------------------|---|--------------------------------|---|---|--|--------------------------------------|--|--|--|
| 1. Name and Address of Reporting Person*  Kirchgraber Paul R                             |   |  |   |          |                              | 2. Issuer Name and Ticker or Trading Symbol LABORATORY CORP OF AMERICA HOLDINGS [ LH ] |  |   |               |   |                         |   |                                | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify |   |  |                                      |  |  |  |
| (Last) (First) (Middle) 531 SOUTH SPRING STREET  |   |  |   |          |                              | 3. Date of Earliest Transaction (Month/Day/Year) 02/21/2023                            |  |   |               |   |                         |   |                                | X Officer (give fille Other (specify below)  CEO, Covance Drug Development  |   |  |                                      |  |  |  |
| (Street) BURLIN (City)   | BURLINGTON NC 27215   |  |   |          |                              |  | 4. If Amendment, Date of Original Filed (Month/Day/Year) |   |               |   |                         |   |                                |   | Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |                                      |  |  |  |
|  |   | Tah  | le I -  | Non-Deri | vativ                        | e Sec  | ·urit  | ies A                                   | canir         | ed D  | isnosed o               | of or F   | Renefic                        | rially  | Owned   | <u> </u>   |                                      |  |  |  |
| Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye |   |  |   |          |                              | n 2A. Deemed<br>Execution Date,  |  | 3.<br>Transaction<br>Code (Instr.<br>8) |               | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and |                         |   |                                | 5. Amou<br>Securiti<br>Benefic<br>Owned   | es Form<br>ally (D) of<br>Following (I) (II   |  | n: Direct<br>or Indirect<br>ostr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership                      |  |  |
|  |   |  |   |          |                              |  |  |   | Code          | v   | Amount                  | (A) or<br>(D)   | Price                          |   | Reporte<br>Transac<br>(Instr. 3   | tion(s)  |                                      |  | (Instr. 4)   |  |
| Common Stock 02/21/202   |   |  |   |          |                              |  | 3  |   | М             |   | 3,000                   | Α   | \$182                          | 2.51  | 17,069  |  |                                      | D  |  |  |
| Common Stock 02/21/2023  |   |  |   |          |                              | 3  |  | S                                       |               | 8,000   | D                       | \$250.5   | 844 <sup>(1)</sup>             | 9,  | 9,069   |  | D                                    |  |  |  |
|  |   | ٦  | Гablе   |          |                              |  |  |   |               |   | sposed of<br>, converti |   |                                |   | wned  |  |                                      |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                      | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |          | 4.<br>Transa<br>Code (<br>8) |  |  |   | Expira        | te Exerc<br>ation Da<br>th/Day/Y                                  |                         | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Secur<br>(Instr. 3 and 4) |                                | S<br>(I   | . Price of<br>erivative<br>ecurity<br>nstr. 5)  | 9. Number<br>derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | e<br>s<br>ully                       | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |  |   |          | Code                         | v  | (A)  | (D)                                     | Date<br>Exerc | isable  | Expiration<br>Date      | Title   | Amo<br>or<br>Num<br>of<br>Shar | ber   |   |  |                                      |  |  |  |
| Non-<br>qualified<br>Stock<br>Options <sup>(2)</sup>                                     | \$182.51  | 02/21/2023                                 |   |          | M                            |  |  | 3,000                                   | 02/04         | /2021 <sup>(3)</sup>  | 02/03/2030              | Comm<br>Stocl   |                                | 00  | \$0   | 4,300  |                                      | D  |  |  |

## **Explanation of Responses:**

- 1. The price of \$250.5844 per share represents a weighted average of sales prices ranging from \$250.44 to \$250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- 2. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- 3. The option vested in three equal annual installments beginning on the date reflected in this column.

/s/ Sandra van der Vaart,

Attorney-in-Fact for Paul R. 02/23/2023

**Kirchgraber** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.